← Back to news

Markets

Fabrinet Just Lost Billions in Market Value Due to Nvidia. Here’s Why the Reaction Is Overdone.

Y

You Can Now Deduct Car Loan Interest but Only if the Final Assembly Happened in America. Here’s How to Check If a Car Qualifies

Y

Alkane Resources uncovers new high-grade gold-antimony domain at Costerfield

Y

The AI Debt Boom Is Helping Push Everyone’s Cost of Capital Higher

Y

Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?

Y

Pfizer’s Turnaround is Gaining Traction, but Can New Products Offset its Patent Cliff?

Y

Retirees can supplement their Social Security with two top dividend stocks

Y

Is Johnson & Johnson’s $5.5 Billion Talc Settlement a Buy Signal, or Is the Legal Risk Far From Over?

Y

Diesel Crisis Threatens to Outlast the Middle East War

Y

Bitwise Just Took $1.8 Billion in a Bear Market, Tom Lee Noticed

Y

A Tax Strategy So Aggressive It Built the World’s Largest Hedge Fund and Made Losing Money the Hottest Product on Wall Street

Y

Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?

Y

The Cannabis M&A Wave Is Here. Curaleaf Proved It. Here's Whether Green Thumb Should Ride It -- or Wait to Be Swept Up.

Y

Prediction: Oklo Won't Book Its First Commercial Power Revenue Before 2028

Y

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

Y

The next big oil trade may have nothing to do with oil stocks

Y

Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?

Y

The $70M business behind Ballerina Farm

Y

Mark Walter Lieutenant Was Key to Dodgers Owner’s Complex Lending Machine

Y

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Y

Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can

Y

The “Crummey Letter”: The One-Page Note Families Mail Every December to Keep a Million-Dollar Trust Tax-Free.

Y

Goldman Sachs spots huge twist ahead of Nvidia’s earnings

Y

Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?

Y

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Y

Micron CEO is doubling down on a cycle-free future

Y

Tesla Maintained Its Majority of the U.S. EV Market in Q2, but That's Not All You Need to Know

Y

Does Billionaire Bill Ackman Know Something Wall Street Doesn’t? He Invested in These 2 Stocks That Have Dropped 33% and 18% Over the Past Year

Y

Celebrity brand whiskey distillery enters Chapter 7 liquidation

Y

How To Earn $500 A Month From Intuit Stock Ahead Of Q4 Earnings

Y

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run

Y

The Metals Company Is Riding the Critical Metals Boom. Here's Why I Still Wouldn't Touch It.

Y

One Social Security Move Boomers Used to Boost Their Checks Is Now Off-Limits to Almost Everyone Else.

Y

Pemex and Petrobras Bet Big on High-Risk High-Reward Drilling Off Mexico

Y

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Y

SK Hynix Is Buying Back 3.3% of Its Shares and Canceling Every One

Y

CHAT vs. FTEC: Is Concentrated AI Exposure or Broad Tech Diversification the Better Play Right Now?

Y

The Custodial Account You Opened for Your Grandson Becomes Legally His the Day He Turns 21, and He Can Spend It on a Car. A 529 Never Does.

Y

This Company Just Paid Out $6.8 Billion. Its AI Bill Was 4x That

Y

If a Bear Market Is Coming, Here's What All of the Smartest Investors Are Doing Right Now

Y

Jim Cramer Says Stocks and the Economy Are Telling Two Very Different Stories: ‘Jarring Gulf’

Y

UBS revamps S&P 500 target for rest of 2026

Y

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

Y

Oracle vs. Amazon: Which Is the Better AI Cloud Stock to Own for the Next 5 Years?

Y

$22 Billion in Customer Deposits Did Not Stop This Chip CEO From Selling $37 Million

Y

Billionaire Druckenmiller makes cancer stock his #1 buy for a reason

Y

After Buying Circle Through a 42% Drop, Cathie Wood Says Analysts Cannot Fathom It

Y

Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?

Y

Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?

Y

Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?

Y